Neurocrine (NBIX) Biosciences announced top-line data from a Phase 4 study, KINECT-PRO, demonstrating clinically meaningful and sustained effects of INGREZZA capsules on the physical, social and ...

In this article, we are going to take a look at where Neurocrine (NASDAQ:NBIX) stands against other top insider stock buys and sells in January. Ever heard of the “January effect?” In case you ...

Neurocrine (NBIX) Biosciences announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of investigational compound NBI ...

Neurological therapeutics specialist Neurocrine Biosciences (NASDAQ:NBIX) reported mixed fourth-quarter earnings on Thursday, Feb. 6. Despite a slight miss on revenue expectations, its adjusted ...